Novo Nordisk and Eli Lilly Battle for a Slice of India’s Obesity Market | Vantage with Palki Sharma

Novo Nordisk and Eli Lilly Battle for a Slice of India’s Obesity Market | Vantage with Palki Sharma

2024 saw weight-loss drugs take the world by storm—Ozempic, Wegovy, and others became household names. But in India? They’re still missing. That’s about to change as global giants like Novo Nordisk and Eli Lilly battle for a slice of India’s obesity market. With 80 million obese and another 225 million overweight, India is a lucrative yet untapped market. Meanwhile, local pharma giants and patent expirations are shaking things up. Palki Sharma tells you more.